Money

Found 79,792 articles

• IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes

  5/18/2023

  IQVIA Holdings Inc. announced that its wholly-owned subsidiary, IQVIA Inc., priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 and $500,000,000 in aggregate principal amount of senior notes due 2030.

• Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 18, 2023

  5/18/2023

  Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 128,840 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

• Editas Medicine Reports Inducement Grant to New Chief Financial Officer - May 18, 2023

  5/18/2023

  Editas Medicine, Inc., a clinical-stage genome editing company, announced the grant of an inducement award to the Company’s newly appointed Chief Financial Officer, Erick Lucera.

• Centinel Spine® Announces Record Worldwide Motion Preservation Revenue in First Quarter 2023

  5/18/2023

  Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-proven total disc replacement technology platform in the world, announced record first quarter 2023 worldwide financial results in its Motion Preservation business.

• Cabaletta Bio Announces Pricing of Public Offering of Common Stock - May 18, 2023

  5/18/2023

  Cabaletta Bio, Inc. announced the pricing of an underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $12.00 per share.

• Following Completed Share Exchange Agreement with ByoPlanet, Plandai Announces Material Rebranding to Disinfectant Industry Focus

  5/18/2023

  Plandai Biotechnology is pleased to announce a comprehensive rebranding initiative following the successful completion of its share exchange agreement with ByoPlanet, LLC.

• Synthetic Biology Industry Raises $US10.3 Billion in 2022 with Largest Investments in Synbio Applications, Bio-CAD, and Gene Synthesis and Sequencing with Strong Growth Expected

  5/18/2023

  After record-setting investment peaks in FY 2020 and 2021 for synthetic biology, the field raised $10.3 billion in 2022.

• Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 18, 2023

  5/18/2023

  Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 810 shares of common stock of the company and 31,690 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company.

• OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  5/18/2023

  OncoSec Medical Incorporated announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, priced at-the-market under Nasdaq rules.

• Paradromics Raises $33 Million in Funding, Achieves Breakthrough Medical Device Designation from FDA

  5/18/2023

  Paradromics Inc., the leading developer of high data-rate brain-computer interfaces (BCI), today announced a $33 million Series A funding round led by Prime Movers Lab.

• 

  CVS Health Winding Down Clinical Trial Business  

  5/17/2023

  Less than two years after announcing the launch of its clinical trial services business, CVS Health reported that it will shut down the division by the end of 2024.

• NIH Awards $14.4 Million to NDRI to Collaborate on the Somatic Mosaicism across Human Tissues (SMaHT) Network

  5/17/2023

  The National Disease Research Interchange, in collaboration with the University of Maryland School of Medicine and Johns Hopkins All Children’s Hospital, has been awarded a research grant of $14.4M by the National Institutes of Health with a goal to transform our knowledge of how much genetic variation there is in cells and tissues throughout our bodies.

• ByoPlanet Announces Completion of Share Exchange Agreement with Plandai Biotechnology

  5/17/2023

  Plandai Biotechnology, Inc. announce the completion of a share exchange agreement whereby PLPL shall acquire one hundred percent of the issued and outstanding ByoPlanet Interests and ByoPlanet's fixed tangible and intangible assets in exchange for all authorized, issued, and outstanding PLPL Preferred Common Shares and Common Stock.

• Cadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation Therapy

  5/17/2023

  Cadence Neuroscience announced today that it has secured $26 million in Series B financing.

• XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

  5/17/2023

  Xbiotech Inc. announced that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest.

• Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan

  5/17/2023

  Sirnaomics Ltd. has received approval of an HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation, which will be used to accelerate research and development of its leading RNAi drug candidate, STP122G, a GalNAc-based innovative anticoagulant therapeutic.

• EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

  5/17/2023

  Exact Sciences announced today that it awarded $1.1 million to 18 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program.

• NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

  5/17/2023

  NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the for the first quarter of 2023.

• Evofem Biosciences Announces 1-for-125 Reverse Stock Split

  5/17/2023

  Evofem Biosciences, Inc., announced a 1-for-125 reverse stock split of the Company's common stock, which was approved by the stockholders of the Company at the special meeting of stockholders held on March 15, 2023.

• Monogram Orthopaedics Announces Closing of Public Offering of $17,216,147

  5/17/2023

  Monogram Orthopaedics Inc. announced it raised $17,216,147 through the sale of 2,374,641 shares of its Class A Common Stock priced at $7.25 per share.